Dianthus Therapeutics, Inc. /DE/ financial data

Symbol
DNTH on Nasdaq
Industry
Pharmaceutical Preparations
Location
300 Technology Square, 8 Th Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Magenta Therapeutics, Inc. (to 9/8/2023)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.68K % +122%
Debt-to-equity 4.19 %
Return On Equity -21 % -128%
Return On Assets -20.2 % +42.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.4M shares -51.6%
Common Stock, Shares, Outstanding 29.4M shares -51.6%
Entity Public Float 32.1M USD
Common Stock, Value, Issued 29K USD -52.5%
Weighted Average Number of Shares Outstanding, Basic 34.2M shares +3812%
Weighted Average Number of Shares Outstanding, Diluted 34.2M shares +3812%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 924K USD -21.2%
Research and Development Expense 47.9M USD +176%
General and Administrative Expense 25M USD +141%
Operating Income (Loss) -68.8M USD -849%
Nonoperating Income (Expense) 12.1M USD +623%
Net Income (Loss) Attributable to Parent -56.7M USD -56.9%
Earnings Per Share, Basic 11.3 USD/shares +96%
Earnings Per Share, Diluted 11.3 USD/shares +96%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 314M USD +680%
Marketable Securities, Current 54.4M USD +20.2%
Accounts Receivable, after Allowance for Credit Loss, Current 840K USD
Other Assets, Current 53K USD +430%
Assets, Current 366M USD +365%
Property, Plant and Equipment, Net 189K USD
Operating Lease, Right-of-Use Asset 442K USD
Assets 369M USD +369%
Accounts Payable, Current 3.7M USD +354%
Employee-related Liabilities, Current 2.6M USD +60.5%
Accrued Liabilities, Current 5.86M USD
Liabilities, Current 10M USD +149%
Operating Lease, Liability, Noncurrent 30K USD
Liabilities 10.7M USD +166%
Accumulated Other Comprehensive Income (Loss), Net of Tax -37K USD -1133%
Retained Earnings (Accumulated Deficit) -121M USD +72.2%
Stockholders' Equity Attributable to Parent 358M USD
Liabilities and Equity 369M USD +369%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD -45.3%
Net Cash Provided by (Used in) Financing Activities 218M USD
Net Cash Provided by (Used in) Investing Activities -5.51M USD -130%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 29.4M shares -51.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 197M USD +2416%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 314M USD +678%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 123M USD +967%
Deferred Tax Assets, Gross 137M USD +1063%
Operating Lease, Liability 407K USD
Depreciation 83K USD +53.3%
Payments to Acquire Property, Plant, and Equipment 245K USD +807%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.7M USD -856%
Lessee, Operating Lease, Liability, to be Paid 434K USD
Property, Plant and Equipment, Gross 331K USD
Operating Lease, Liability, Current 377K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 222K USD -39.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 222K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 27K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 188K USD
Deferred Tax Assets, Operating Loss Carryforwards 73.6M USD +1267%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.06M USD
Operating Lease, Payments 19.8M USD -100%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 7.31M USD +14.7%
Depreciation, Depletion and Amortization 421K USD -17.6%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 6.94M USD
Deferred Tax Assets, Net of Valuation Allowance 13.3M USD +6690%
Share-based Payment Arrangement, Expense 7.04M USD +571%
Operating Leases, Future Minimum Payments, Due in Three Years 7.68M USD +14%
Operating Leases, Future Minimum Payments Due 44.9M USD -9.73%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%